CLVS Stock Recent News
CLVS LATEST HEADLINES
Biotech penny stocks to watch right now. The post Penny Stocks To Buy Now?
Today, investors in Clovis Oncology are cheering about more positive clinical trial results as CLVS stock soars 50%. The post CLVS Stock Alert: 7 Things to Know as Clovis Oncology Soars 70% appeared first on InvestorPlace.
Check these 3 penny stocks out for your watchlist right now The post Best Penny Stocks to Buy This Week? 3 to Watch as June Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
It reported some great initial data from one of its phase 1 clinical trials.
Check these three biotech penny stocks out for your watchlist right now The post 3 Biotech Penny Stocks That Climbed in After-Hours Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Today has been another strong one for investors in Clovis Oncology and CLVS stock, with this company surging another 20% in today's session. The post Clovis Oncology (CLVS) Stock Gains 20% on Tumor Trials, Buyout Hopes appeared first on InvestorPlace.
Clovis Oncology (CLVS) reports favorable data from a study, which supports the potential clinical utility of FAP-2286, its targeted radiotherapy candidate, as a treatment for advanced solid tumors.
Penny Stocks To Watch Right Now The post Best Penny Stocks To Buy Now? 4 To Watch After June's Fed Meeting appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Clovis Oncology Inc (NASDAQ: CLVS) announced a presentation detailing initial Phase 1 data from Phase 1/2 LuMIERE clinical study of FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286). Overall, in nine patients treated in the first two dose cohorts, 177Lu-FAP-2286 demonstrated.
Pharmaceutical startup CLVS stock is climbing 25% higher today on rumors that the cancer drug maker has become a takeover target. The post Clovis Oncology (CLVS) Stock Rallies on Buyout Rumors appeared first on InvestorPlace.